Published in J Am Soc Nephrol on February 20, 2008
Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol (2009) 2.89
Differential scaling of glomerular filtration rate and ingested metabolic burden: implications for gender differences in chronic kidney disease outcomes. Nephrol Dial Transplant (2013) 1.41
The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review. J Am Soc Nephrol (2014) 1.29
The production of p-cresol sulfate and indoxyl sulfate in vegetarians versus omnivores. Clin J Am Soc Nephrol (2012) 1.21
Estimated glomerular filtration rate is a poor predictor of concentration for a broad range of uremic toxins. Clin J Am Soc Nephrol (2011) 1.10
Prognosis of CKD patients receiving outpatient nephrology care in Italy. Clin J Am Soc Nephrol (2011) 1.04
Protein-bound uremic toxins: new insight from clinical studies. Toxins (Basel) (2011) 1.04
Immune dysfunction in uremia—an update. Toxins (Basel) (2012) 1.03
Alteration of the Intestinal Environment by Lubiprostone Is Associated with Amelioration of Adenine-Induced CKD. J Am Soc Nephrol (2014) 1.02
Vascular damage in kidney disease: beyond hypertension. Int J Hypertens (2011) 0.92
Does the adequacy parameter Kt/V(urea) reflect uremic toxin concentrations in hemodialysis patients? PLoS One (2013) 0.90
Bioengineered kidney tubules efficiently excrete uremic toxins. Sci Rep (2016) 0.90
Estimated glomerular filtration rate is a poor predictor of the concentration of middle molecular weight uremic solutes in chronic kidney disease. PLoS One (2012) 0.89
Retained organic solutes, patient characteristics and all-cause and cardiovascular mortality in hemodialysis: results from the retained organic solutes and clinical outcomes (ROSCO) investigators. BMC Nephrol (2013) 0.88
The Aryl Hydrocarbon Receptor is a Critical Regulator of Tissue Factor Stability and an Antithrombotic Target in Uremia. J Am Soc Nephrol (2015) 0.87
Regulatory pathways for ATP-binding cassette transport proteins in kidney proximal tubules. AAPS J (2012) 0.83
Haemocompatibility and ion exchange capability of nanocellulose polypyrrole membranes intended for blood purification. J R Soc Interface (2012) 0.83
Does p-cresylglucuronide have the same impact on mortality as other protein-bound uremic toxins? PLoS One (2013) 0.83
Bisphenol a in chronic kidney disease. Int J Nephrol (2013) 0.82
Serum Indoxyl Sulfate Associates with Postangioplasty Thrombosis of Dialysis Grafts. J Am Soc Nephrol (2015) 0.82
A metabolomic approach to clarifying the effect of AST-120 on 5/6 nephrectomized rats by capillary electrophoresis with mass spectrometry (CE-MS). Toxins (Basel) (2012) 0.80
Protein-Bound Uremic Toxin Profiling as a Tool to Optimize Hemodialysis. PLoS One (2016) 0.80
Magnetic separation-based blood purification: a promising new approach for the removal of disease-causing compounds? J Nanobiotechnology (2015) 0.79
Role of β2-microglobulin in uremic patients may be greater than originally suspected. World J Nephrol (2015) 0.79
Protein-bound solute removal during extended multipass versus standard hemodialysis. BMC Nephrol (2015) 0.78
Home haemodialysis and uraemic toxin removal: does a happy marriage exist? Nat Rev Nephrol (2012) 0.78
Hemodiafiltration: the addition of convective flow to hemodialysis. Pediatr Nephrol (2011) 0.78
Alteration of human blood cell transcriptome in uremia. BMC Med Genomics (2013) 0.77
p-Cresyl Sulfate. Toxins (Basel) (2017) 0.77
Indoxyl sulfate down-regulates SLCO4C1 transporter through up-regulation of GATA3. PLoS One (2013) 0.77
The use of SDS-PAGE scanning of spent dialysate to assess uraemic toxin removal by dialysis. Nephrol Dial Transplant (2010) 0.77
Proteomic analisys of protein extraction during hemofiltration with on-line endogenous reinfusion (HFR) using different polysulphone membranes. J Mater Sci Mater Med (2014) 0.76
Rhubarb Enema Attenuates Renal Tubulointerstitial Fibrosis in 5/6 Nephrectomized Rats by Alleviating Indoxyl Sulfate Overload. PLoS One (2015) 0.76
Optimal hemodialysis prescription: do children need more than a urea dialysis dose? Int J Nephrol (2011) 0.75
Proteomic Investigations into Hemodialysis Therapy. Int J Mol Sci (2015) 0.75
Neurological disorders in a murine model of chronic renal failure. Toxins (Basel) (2014) 0.75
A zebrafish model for uremic toxicity: role of the complement pathway. Blood Purif (2013) 0.75
Cross-sectional examination of metabolites and metabolic phenotypes in uremia. BMC Nephrol (2015) 0.75
Effects of uremic solutes on reactive oxygen species in vitro model systems as a possibility of support the renal function management. BMC Nephrol (2015) 0.75
Worsening Renal Function and Mortality in Heart Failure: Causality or Confounding? Circ Heart Fail (2017) 0.75
Arterial and Cellular Inflammation in Patients with CKD. J Am Soc Nephrol (2016) 0.75
Reduced Microvascular Density in Omental Biopsies of Children with Chronic Kidney Disease. PLoS One (2016) 0.75
Allostimulatory capacity of conditionally immortalized proximal tubule cell lines for bioartificial kidney application. Sci Rep (2017) 0.75
Effects of Sevelamer Hydrochloride on Uremic Toxins Serum Indoxyl Sulfate and P-Cresyl Sulfate in Hemodialysis Patients. J Clin Med Res (2017) 0.75
Body composition monitoring-derived urea distribution volume in children on chronic hemodialysis. Pediatr Nephrol (2016) 0.75
[Low protein diet in the treatment of chronic renal failure: effective, but barely used]. Wien Klin Wochenschr (2008) 0.75
Indoxyl sulfate, a uremic toxin in chronic kidney disease, suppresses both bone formation and bone resorption. FEBS Open Bio (2017) 0.75
Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int (2003) 3.54
Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol (2009) 2.89
Clinical proteomics: A need to define the field and to begin to set adequate standards. Proteomics Clin Appl (2007) 2.84
The ultrafiltration coefficient of a dialyser (KUF) is not a fixed value, and it follows a parabolic function: the new concept of KUF max. Nephrol Dial Transplant (2010) 2.75
Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant (2005) 2.40
Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant (2009) 2.06
The Case | A hip fracture in a hemodialysis patient. Pathologic right-hip fracture from β2-microglobulin amyloidosis. Kidney Int (2013) 2.01
Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol (2012) 1.90
Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics (2010) 1.90
The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int (2004) 1.83
Advances in urinary proteome analysis and biomarker discovery. J Am Soc Nephrol (2007) 1.77
Natural killer cell alterations correlate with loss of renal function and dialysis duration in uraemic patients. Nephrol Dial Transplant (2007) 1.69
Adenosine 5'-tetraphosphate is a highly potent purinergic endothelium-derived vasoconstrictor. Circ Res (2008) 1.61
Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med (2010) 1.59
CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin Appl (2008) 1.57
P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transplant (2006) 1.53
Detection of angiotensin II in supernatants of stimulated mononuclear leukocytes by matrix-assisted laser desorption ionization time-of-flight/time-of-flight mass analysis. Hypertension (2005) 1.52
Characterisation of advanced glycation endproducts in saliva from patients with diabetes mellitus. Biochem Biophys Res Commun (2004) 1.47
Removal of protein-bound, hydrophobic uremic toxins by a combined fractionated plasma separation and adsorption technique. Artif Organs (2013) 1.42
The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation (2003) 1.41
Role of a cysteine synthase in Staphylococcus aureus. J Bacteriol (2004) 1.36
Transcriptional regulation of the Staphylococcus aureus thioredoxin and thioredoxin reductase genes in response to oxygen and disulfide stress. J Bacteriol (2004) 1.36
The gut: the forgotten organ in uremia? Blood Purif (2010) 1.33
Endothelial-derived microparticles: Biological conveyors at the crossroad of inflammation, thrombosis and angiogenesis. Thromb Haemost (2010) 1.30
Protein-bound toxins--update 2009. Semin Dial (2009) 1.28
Vascular incompetence in dialysis patients--protein-bound uremic toxins and endothelial dysfunction. Semin Dial (2011) 1.28
NrdR controls differential expression of the Escherichia coli ribonucleotide reductase genes. J Bacteriol (2007) 1.23
Effective removal of protein-bound uraemic solutes by different convective strategies: a prospective trial. Nephrol Dial Transplant (2008) 1.23
Role of symmetric dimethylarginine in vascular damage by increasing ROS via store-operated calcium influx in monocytes. Nephrol Dial Transplant (2008) 1.23
What is new in uremic toxicity? Pediatr Nephrol (2008) 1.23
Staphylococcus aureus ArcR controls expression of the arginine deiminase operon. J Bacteriol (2007) 1.21
Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease. Clin J Am Soc Nephrol (2011) 1.20
Uridine adenosine tetraphosphate: a novel endothelium- derived vasoconstrictive factor. Nat Med (2005) 1.19
Relationship between magnesium and clinical biomarkers on inhibition of vascular calcification. Am J Nephrol (2011) 1.17
Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients. Kidney Int (2012) 1.16
Coenzyme B12 controls transcription of the Streptomyces class Ia ribonucleotide reductase nrdABS operon via a riboswitch mechanism. J Bacteriol (2006) 1.15
Urinary output and fractional excretion of sodium and urea as indicators of transient versus intrinsic acute kidney injury during early sepsis. Crit Care (2013) 1.15
Indolic uremic solutes increase tissue factor production in endothelial cells by the aryl hydrocarbon receptor pathway. Kidney Int (2013) 1.15
Immunomodulator FTY720 Induces eNOS-dependent arterial vasodilatation via the lysophospholipid receptor S1P3. Circ Res (2005) 1.14
Discovery and characterization of alamandine: a novel component of the renin-angiotensin system. Circ Res (2013) 1.13
Warning: the unfortunate end of p-cresol as a uraemic toxin. Nephrol Dial Transplant (2011) 1.12
Diamide triggers mainly S Thiolations in the cytoplasmic proteomes of Bacillus subtilis and Staphylococcus aureus. J Bacteriol (2009) 1.12
High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A. Cardiovasc Res (2012) 1.11
Uraemic toxins and cardiovascular disease. Nephrol Dial Transplant (2003) 1.11
Mass-spectrometric identification of a novel angiotensin peptide in human plasma. Arterioscler Thromb Vasc Biol (2006) 1.10
Estimated glomerular filtration rate is a poor predictor of concentration for a broad range of uremic toxins. Clin J Am Soc Nephrol (2011) 1.10
Incidence of post myocardial infarction left ventricular thrombus formation in the era of primary percutaneous intervention and glycoprotein IIb/IIIa inhibitors. A prospective observational study. Cardiovasc Ultrasound (2006) 1.06
High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity. Kidney Int (2003) 1.06
The Streptomyces NrdR transcriptional regulator is a Zn ribbon/ATP cone protein that binds to the promoter regions of class Ia and class II ribonucleotide reductase operons. J Bacteriol (2006) 1.05
A multidomain fusion protein in Listeria monocytogenes catalyzes the two primary activities for glutathione biosynthesis. J Bacteriol (2005) 1.05
Alternative oxygen-dependent and oxygen-independent ribonucleotide reductases in Streptomyces: cross-regulation and physiological role in response to oxygen limitation. Mol Microbiol (2004) 1.04
p-Cresyl sulfate promotes insulin resistance associated with CKD. J Am Soc Nephrol (2013) 1.04
Toxicity of free p-cresol: a prospective and cross-sectional analysis. Clin Chem (2003) 1.03
Streptomyces spp. contain class Ia and class II ribonucleotide reductases: expression analysis of the genes in vegetative growth. Microbiology (2002) 1.03
P-cresol, a uremic toxin, decreases endothelial cell response to inflammatory cytokines. Kidney Int (2002) 1.02
Implementation of proteomic biomarkers: making it work. Eur J Clin Invest (2012) 1.00
Human parvovirus 4 in kidney transplant patients, France. Emerg Infect Dis (2008) 1.00
Dialysis water and fluid purity: more than endotoxin. Nephrol Dial Transplant (2012) 1.00
Novel method for simultaneous determination of p-cresylsulphate and p-cresylglucuronide: clinical data and pathophysiological implications. Nephrol Dial Transplant (2011) 1.00
Guanidino compounds as uremic (neuro)toxins. Semin Dial (2009) 0.99
Adsorption of the uremic toxin p-cresol onto hemodialysis membranes and microporous adsorbent zeolite silicalite. J Biotechnol (2006) 0.99
Soluble CD146, a novel endothelial marker, is increased in physiopathological settings linked to endothelial junctional alteration. Thromb Haemost (2003) 0.98
Transmission of hepatitis C virus between hemodialysis patients sharing the same machine. Infect Control Hosp Epidemiol (2004) 0.98
The middle-molecule hypothesis 30 years after: lost and rediscovered in the universe of uremic toxicity? J Nephrol (2008) 0.98
Quantitative testing of robustness on superomniphobic surfaces by drop impact. Langmuir (2010) 0.97
Differential effects of uridine adenosine tetraphosphate on purinoceptors in the rat isolated perfused kidney. Br J Pharmacol (2010) 0.97
Zipping effect on omniphobic surfaces for controlled deposition of minute amounts of fluid or colloids. Small (2012) 0.96
New insights in uremic toxins. Kidney Int Suppl (2003) 0.96
p-cresyl sulphate has pro-inflammatory and cytotoxic actions on human proximal tubular epithelial cells. Nephrol Dial Transplant (2013) 0.95
Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis. Nephrol Dial Transplant (2003) 0.95
Determination of insoluble, soluble, and total dietary fiber (CODEX definition) by enzymatic-gravimetric method and liquid chromatography: collaborative study. J AOAC Int (2012) 0.94
Functional analysis of the Streptomyces coelicolor NrdR ATP-cone domain: role in nucleotide binding, oligomerization, and DNA interactions. J Bacteriol (2008) 0.94
Characterization of polymer membranes by MALDI mass-spectrometric imaging techniques. Anal Chem (2013) 0.94
Guanidino compounds as cause of cardiovascular damage in chronic kidney disease: an in vitro evaluation. Blood Purif (2010) 0.92
Review on uraemic toxins III: recommendations for handling uraemic retention solutes in vitro--towards a standardized approach for research on uraemia. Nephrol Dial Transplant (2007) 0.92
Influence of severity of illness on neutrophil gelatinase-associated lipocalin performance as a marker of acute kidney injury: a prospective cohort study of patients with sepsis. BMC Nephrol (2015) 0.92
Genetics/Genomics in chronic kidney disease--towards personalized medicine? Semin Dial (2009) 0.92
P-cresol, a uremic retention solute, alters the endothelial barrier function in vitro. Thromb Haemost (2004) 0.92
Staphylococcus aureus NrdH redoxin is a reductant of the class Ib ribonucleotide reductase. J Bacteriol (2010) 0.91
An update on protein-bound uremic retention solutes. J Ren Nutr (2012) 0.91
Does the adequacy parameter Kt/V(urea) reflect uremic toxin concentrations in hemodialysis patients? PLoS One (2013) 0.90
Dinucleoside polyphosphates: strong endogenous agonists of the purinergic system. Br J Pharmacol (2009) 0.90
Platelet/Leukocyte activation, inflammation, and uremia. Semin Dial (2009) 0.90
Comparison of removal capacity of two consecutive generations of high-flux dialysers during different treatment modalities. Nephrol Dial Transplant (2011) 0.90